Ainos, Inc. (AIMD)
Nasdaq · Technology · Scientific & Technical Instruments
$1.33−1.70%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $9.8M
- 52-week range
- $1.20 – $4.44
- 52-week change
- −64.95%
- EPS (trailing)
- −$2.54
Fiscal year to Dec 2025
- Revenue
- $124K (+498.97%)
- Net income
- −$14.8M
- Operating margin
- −11267.7%
- Diluted EPS
- −$3.46
- Free cash flow
- −$4.7M
From the company’s annual report on SEC EDGAR.
About Ainos, Inc.
Ainos, Inc., a dual-platform company, focusing artificial intelligencebased smelltech technologies and immune therapeutics. It offers AI Nose, an AI-based electronic olfaction system, which uses a smell language model to digitize scent into Smell IDs and turning into machine-readable data. The company provides its platforms for semiconductor manufacturing, robotics, and smart manufacturing industries; as well as senior care and women's health sectors. In addition, it develops VELDONA, a low-dose oral interferon platform for human and animal health applications, targeting rare, autoimmune, and infectious diseases. The company was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. Ainos, Inc. was incorporated in 1984 and is based in Houston, Texas. Ainos, Inc. is a subsidiary of Taiwan Carbon Nano Technology Corporation.
Headquarters: Houston, United States · 41 employees · ainos.com